Literature DB >> 18097699

[Treating travelers' diarrhea. When should medication be given?].

G Birkenfeld1.   

Abstract

Along with the dizzying rise in the world's population and economic globalization, travel activity has also increased. Travelers' diarrhea, caused by changed sanitary conditions, has a very different pathogenic spectrum and clinical course from those of our native forms of infectious enterocolitis. Awareness of the warning signs of complications in the clinical course and of the differential diagnoses is therefore a prerequisite for rational therapy. This covers oral rehydration, motility inhibitors, adsorbents, antisecretory agents, probiotics, and last but not least the use of antibiotics, which make an essential contribution if correctly used. There are interesting developments in the form of nonabsorbable antibiotics and new antisecretory agents, which inhibit protein synthesis and enzymes and are increasingly used as antidiarrheal agents with few side effects. In the combination of various therapeutic options in travelers' diarrhea there is still much scope for research. The priority is the correct implementation of the options available today, in order to avoid, as far as possible, therapeutic setbacks and the development of resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18097699     DOI: 10.1007/s00108-007-1985-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  16 in total

1.  Comparison of racecadotril and loperamide in children with acute diarrhoea.

Authors:  D Turck; H Berard; N Fretault; J M Lecomte
Journal:  Aliment Pharmacol Ther       Date:  1999-12       Impact factor: 8.171

2.  Efficacy and tolerability of racecadotril in acute diarrhea in children.

Authors:  J P Cézard; J F Duhamel; M Meyer; I Pharaon; M Bellaiche; C Maurage; J L Ginies; J M Vaillant; J P Girardet; T Lamireau; A Poujol; A Morali; J Sarles; J P Olives; C Whately-Smith; S Audrain; J M Lecomte
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

3.  Rifaximin treatment of pathogen-negative travelers' diarrhea.

Authors:  Herbert L DuPont; Robert Haake; David N Taylor; Charles D Ericsson; Zhi-Dong Jiang; Pablo C Okhuysen; Robert Steffen
Journal:  J Travel Med       Date:  2007 Jan-Feb       Impact factor: 8.490

4.  Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.

Authors:  Javier A Adachi; Herbert L DuPont
Journal:  Clin Infect Dis       Date:  2006-01-17       Impact factor: 9.079

5.  Racecadotril in the treatment of acute watery diarrhea in children.

Authors:  E Salazar-Lindo; J Santisteban-Ponce; E Chea-Woo; M Gutierrez
Journal:  N Engl J Med       Date:  2000-08-17       Impact factor: 91.245

Review 6.  Rifaximin: a review of its use in the management of traveller's diarrhoea.

Authors:  Gayle W Robins; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study].

Authors:  H Kollaritsch; H Holst; P Grobara; G Wiedermann
Journal:  Fortschr Med       Date:  1993-03-30

Review 8.  Epidemiologic studies of travelers' diarrhea, severe gastrointestinal infections, and cholera.

Authors:  R Steffen
Journal:  Rev Infect Dis       Date:  1986 May-Jun

9.  Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent.

Authors:  R A Kuschner; A F Trofa; R J Thomas; C W Hoge; C Pitarangsi; S Amato; R P Olafson; P Echeverria; J C Sadoff; D N Taylor
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

10.  Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea.

Authors:  I Salam; P Katelaris; S Leigh-Smith; M J Farthing
Journal:  Lancet       Date:  1994-12-03       Impact factor: 79.321

View more
  1 in total

Review 1.  [Drug therapy of infectious diarrhea. Part 2: Chronic diarrhea].

Authors:  C Lübbert; S Weis
Journal:  Internist (Berl)       Date:  2013-12       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.